B7-H3 (CD276): Dual-Function Immune Checkpoint with Conflicting Oncogenic and Immunomodulatory Activities

Genomic and Structural Features Distinguishing Human and Murine B7-H3 Isoforms

B7-H3, officially annotated CD276, belongs to the B7-CD28 superfamily of co-regulatory immune transmembrane glycoproteins encoded at human chromosomal locus 15q24.1. Human cells generate two distinct splice variants via ancestral exon duplication events: 2Ig-B7-H3 with paired IgV-IgC domains and dominant 4Ig-B7-H3 carrying tandem dual Ig domain repeats. Murine B7-H3 exclusively expresses the shorter 2Ig structural isoform with 88 primary amino acid sequence homology to human orthologs. All functional variants share a single extracellular signal peptide, paired immunoglobulin folds, short transmembrane anchor and truncated cytoplasmic tail lacking intrinsic kinase catalytic motifs. Proteolytic cleavage of membrane-bound B7-H3 by matrix metalloproteinases releases soluble sB7-H3 protein into interstitial fluid and peripheral plasma compartments for systemic immune signaling modulation in tumor culture models.

Dual Immunomodulatory Roles of B7-H3 in T Cell Activation Cascades

Two opposing functional phenotypes have been documented for B7-H3 across independent primary immune co-culture experiments. Early in vitro co-stimulation assays demonstrate B7-H3 fusion proteins boost CD4+ and CD8+ T cell proliferation alongside elevated IFN-γ, IL-2 and IL-12 cytokine secretion profiles. Follow-up large-scale cohort studies identify dominant co-inhibitory capacity that suppresses core TCR downstream transcription factors NFAT, AP-1 and NF-κB. This dual regulatory capacity drives lineage-specific T cell polarization bias: B7-H3 restrains Th1-type IFN-γ output while amplifying Th2 and Th17 cytokine production including IL-4, IL-10 and IL-17. The unconfirmed primary cell-surface receptor TLT2 represents one proposed binding partner, yet unidentified co-inhibitory receptors likely mediate context-dependent suppressive signal transduction within heterogeneous tissue microenvironments.

Tissue and Tumor-Specific B7-H3 Expression Gradients

Restrictive translational control limits B7-H3 protein abundance on resting normal somatic cells despite widespread low-level mRNA transcription across hepatic, intestinal and cardiac tissues. Surface protein expression sharply rises on activated monocytes, dendritic cells and lymphocytes stimulated by LPS or GM-CSF cytokine exposure. Broad-spectrum overexpression is consistently measured across solid tumor cell lines including lung, breast, pancreatic, cervical and hepatocellular carcinoma cultures. Circulating soluble sB7-H3 concentrations correlate with malignant lesion staging in NSCLC and pancreatic preclinical model cohorts. B7-H3 prognostic correlation displays tumor-subtype heterogeneity: elevated protein levels associate with accelerated progression in most carcinoma lines yet predict extended survival in selected gastric and pancreatic tumor subpopulations.

B7-H3-Mediated Intracellular Signaling Driving Malignant Progression

Beyond immune evasion mechanisms, membrane-bound and soluble B7-H3 directly activate multiple oncogenic kinase axes within malignant epithelial cell populations. Core downstream cascades include PI3K/AKT, JAK2/STAT3 and canonical NF-κB transcriptional networks that amplify proliferative, migratory and anti-apoptotic gene expression programs. Soluble sB7-H3 engages TLT4 receptors on stromal cells to upregulate VEGF and IL-8 angiogenic chemokines, expanding vascular supply for growing tumor spheroids. B7-H3 also modulates chromatin modifier activity to remodel epigenetic landscapes that sustain epithelial-mesenchymal transition (EMT) invasive phenotypes. Variable microenvironmental cytokine balances shift B7-H3 signaling output between pro-tumor and growth-restrictive transcriptional programs across distinct culture and in vivo experimental systems.

Six Categories of Preclinical B7-H3 Targeted Intervention Modalities

Diversified research tools and therapeutic candidates leverage tumor-selective B7-H3 surface abundance without universal reliance on ligand-receptor neutralization. Fc-engineered recombinant antibodies such as enoblituzumab mediate robust ADCC effector clearance of B7-H3-positive malignant cells in syngeneic xenograft cohorts. Radioisotope-conjugated anti-B7-H3 tracers enable whole-body molecular imaging and targeted radiation delivery for neuroblastoma preclinical assays. B7-H3-directed antibody-drug conjugates deliver cytotoxic payloads via receptor-mediated endocytosis pathways. CAR-T cell constructs incorporating B7-H3 antigen-recognition extracellular domains eliminate solid tumor spheroids in pediatric sarcoma model systems. Bispecific antibodies crosslink B7-H3 and CD3 to redirect endogenous T cell cytotoxicity toward antigen-expressing tumor targets. Pure blocking antibodies remain in early-stage screening due to incomplete receptor identification barriers limiting standardized neutralization assay design.

Core Unresolved Research Barriers Limiting B7-H3 Mechanistic Translation

Four consistent experimental bottlenecks delay uniform interpretation of B7-H3 dual biological functions across preclinical screening pipelines. Complete identification of all cell-surface receptors mediating inhibitory versus co-stimulatory signal transduction remains unfulfilled. Tissue microenvironment and tumor subtype-dependent functional switching creates divergent experimental readouts between separate cell line cohorts. Lack of globally standardized IHC scoring protocols impairs cross-study comparison of B7-H3 biomarker expression datasets. Combinatorial treatment timing and dosage pairing with PD-1 checkpoint reagents, radiation or small molecule inhibitors require systematic stratified screening to define synergistic co-administration schedules.

B7-H3 Recombinant Rabbit Antibodies from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. develops two specificity-validated recombinant rabbit anti-B7-H3 mAb clones optimized for multi-platform tumor immunology profiling workflows. Clone S0B2244 (SDT-249-26) delivers crisp membranous staining on FFPE solid tumor tissue sections with minimal cytoplasmic non-specific background signals. Bulk PBS-only purified formulation S0B2244P supports large-volume custom fluorophore or radioisotope conjugation for in vivo imaging probe construction. Clone S0B2334 (SDT-1333-8) is engineered for flow cytometry immunophenotyping of dissociated single-cell tumor suspensions. Every antibody batch undergoes peptide competition knockout cell line validation to eliminate off-target cross-recognition of homologous B7 superfamily paralogs. Rigorous recombinant production workflows stabilize epitope binding affinity to minimize lot-to-lot signal variation for longitudinal biomarker cohort analysis.

Fundamental Research Applications of ANT BIO PTE. LTD. Anti-B7-H3 Antibodies

FFPE tumor tissue microarray IHC quantifies membranous B7-H3 expression gradients to stratify high and low antigen-expressing preclinical model subgroups. Multi-color flow cytometry co-staining pairs anti-B7-H3 with immune checkpoint markers to map tumor microenvironment immune cell infiltration patterns. Western blot analysis detects total and soluble B7-H3 protein abundance within cell lysate and culture supernatant matrices. Immunoprecipitation assays isolate B7-H3 receptor binding complexes to identify uncharacterized surface interaction partners. Immunofluorescence spatial profiling visualizes B7-H3 co-localization with EMT and angiogenic biomarkers across heterogeneous lesion microdomains. High-throughput compound screening tracks dynamic B7-H3 expression shifts following epigenetic or immunomodulatory co-culture treatment cycles.

ANT BIO PTE. LTD. B7-H3 Recombinant Rabbit Antibody Portfolio

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.